These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 24649264)

  • 1. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
    Douillard JY; Ostoros G; Cobo M; Ciuleanu T; Cole R; McWalter G; Walker J; Dearden S; Webster A; Milenkova T; McCormack R
    J Thorac Oncol; 2014 Sep; 9(9):1345-53. PubMed ID: 25122430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
    Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
    Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer.
    Yuan Y; Li XF; Chen JQ; Dong CX; Weng SS; Huang JJ
    Onco Targets Ther; 2014; 7():841-52. PubMed ID: 24920926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of Killing Effect of Thioridazine on Human Lung Cancer PC9 Cells].
    Gong L; Wang Y; Tong S; Liu L; Niu L; Yuan Y; Bao Y
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):727-33. PubMed ID: 26706948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib.
    Song Z; Zhang Y
    Mol Clin Oncol; 2013 Sep; 1(5):875-878. PubMed ID: 24649264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.
    Xia GH; Zeng Y; Fang Y; Yu SR; Wang L; Shi MQ; Sun WL; Huang XE; Chen J; Feng JF
    Cancer Biol Med; 2014 Dec; 11(4):270-6. PubMed ID: 25610713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
    Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
    Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
    BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
    Tang C; Li X; Guo W; Li J; Qin H; Wang W; Qu L; An J; Gao H; Liu X
    Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
    Goldberg SB; Oxnard GR; Digumarthy S; Muzikansky A; Jackman DM; Lennes IT; Sequist LV
    Oncologist; 2013; 18(11):1214-20. PubMed ID: 24072220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
    Chaft JE; Oxnard GR; Sima CS; Kris MG; Miller VA; Riely GJ
    Clin Cancer Res; 2011 Oct; 17(19):6298-303. PubMed ID: 21856766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.